Please use this identifier to cite or link to this item:
Type: Artigo
Title: Cutaneous Wound Healing Through Paradoxical Mapk Activation By Braf Inhibitors
Author: Escuin-Ordinas
Helena; Li
Shuoran; Xie
Michael W.; Sun
Lu; Hugo
Willy; Huang
Rong Rong; Jiao
Jing; de-Faria
Felipe Meira; Realegeno
Susan; Krystofinski
Paige; Azhdam
Ariel; Komenan
Sara Marie D.; Atefi
Mohammad; Comin-Anduix
Begona; Pellegrini
Matteo; Cochran
Alistair J.; Modlin
Robert L.; Herschman
Harvey R.; Lo
Roger S.; McBride
William H.; Segura
Tatiana; Ribas
Abstract: BRAF inhibitors are highly effective therapies for the treatment of BRAF(V600)-mutated melanoma, with the main toxicity being a variety of hyperproliferative skin conditions due to paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway in BRAF wild-type cells. Most of these hyperproliferative skin changes improve when a MEK inhibitor is co-administered, as it blocks paradoxical MAPK activation. Here we show how the BRAF inhibitor vemurafenib accelerates skin wound healing by inducing the proliferation and migration of human keratinocytes through extracellular signal-regulated kinase (ERK) phosphorylation and cell cycle progression. Topical treatment with vemurafenib in two wound-healing mice models accelerates cutaneous wound healing through paradoxical MAPK activation; addition of a mitogen-activated protein kinase kinase (MEK) inhibitor reverses the benefit of vemurafenib-accelerated wound healing. The same dosing regimen of topical BRAF inhibitor does not increase the incidence of cutaneous squamous cell carcinomas in mice. Therefore, topical BRAF inhibitors may have clinical applications in accelerating the healing of skin wounds.
Subject: Squamous-cell Carcinomas
Mouse Skin
Editor: Nature Publishing Group
Citation: Nature Communications. Nature Publishing Group, v. 7, p. , 2016.
Rights: aberto
Identifier DOI: 10.1038/ncomms12348
Date Issue: 2016
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
000380853600001.pdf2.54 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.